Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for In-Vitro Permeation Testing (IVPT) – V 2.0

Posted on By

Analytical Method Development: SOP for In-Vitro Permeation Testing (IVPT) – V 2.0

Standard Operating Procedure for In-Vitro Permeation Testing (IVPT) in Topical and Transdermal Formulations


Department Analytical Method Development
SOP No. SOP/AMD/181/2025
Supersedes SOP/AMD/181/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

To establish a standardized procedure for conducting In-Vitro Permeation Testing (IVPT) of topical and transdermal pharmaceutical products to evaluate drug diffusion across membranes using

Franz diffusion cell apparatus.

2. Scope

This SOP applies to the Analytical Method Development (AMD) team responsible for assessing the release and permeation profiles of creams, gels, ointments, lotions, and transdermal patches under controlled lab conditions.

3. Responsibilities

  • Analytical Scientist: Develops method protocol, selects membrane type, and evaluates diffusion profiles.
  • Lab Analyst: Prepares membranes, samples, maintains apparatus conditions, and performs sample collection.
  • QA Officer: Reviews test setup, data integrity, and regulatory compliance.
  • Head – AMD: Approves final IVPT method and ensures regulatory alignment for submissions.
See also  Analytical Method Development: SOP for Water for Injection (WFI) Quality Testing Method - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring that IVPT studies are performed with scientific rigor, reproducibility, and regulatory compliance.

5. Procedure

5.1 Equipment and Setup

  1. Use vertical Franz diffusion cells with receptor volume: 5–10 mL and effective diffusion area: 0.64–2.0 cm².
  2. Maintain receptor fluid temperature at 32 ± 1°C (skin surface temperature).
  3. Use magnetic stirrers to maintain receptor fluid homogeneity (300–600 rpm).

5.2 Membrane Selection and Preparation

  1. Select appropriate membranes:
    • Synthetic (e.g., cellulose acetate, PVDF) for release studies.
    • Biological (e.g., porcine skin, human cadaver skin) for permeation studies.
  2. Hydrate synthetic membranes in receptor fluid for at least 1 hour before use.
  3. For biological membranes, thaw, inspect integrity, and equilibrate as per protocol.

5.3 Receptor Medium

  1. Select receptor fluid (e.g., PBS, ethanol-PBS mix) based on solubility and sink conditions.
  2. Degas medium and filter using 0.22 µm membrane before filling cells.

5.4 Application of Test Product

  1. Accurately weigh required dose of test sample (typically 2–5 mg/cm² for semi-solids).
  2. Evenly apply on the donor side of membrane using a spatula or dosing ring.
  3. Cover donor compartment with Parafilm to prevent evaporation.
See also  Analytical Method Development: SOP for Conducting Forced Degradation Study - V 2.0

5.5 Sample Collection and Analysis

  1. Withdraw fixed volume (e.g., 200 µL) of receptor fluid at predetermined time intervals (e.g., 0.5, 1, 2, 4, 6, 8 hours).
  2. Replace withdrawn volume with fresh, pre-warmed receptor fluid.
  3. Analyze samples using validated HPLC or UV method to quantify drug content.
  4. Document in Annexure-1: IVPT Sample Log.

5.6 Data Analysis

  1. Calculate cumulative amount permeated per unit area (µg/cm²).
  2. Plot cumulative permeated amount vs. time to determine flux (µg/cm²/h).
  3. Calculate lag time and steady-state permeability coefficient (Kp).
  4. Summarize in Annexure-2: IVPT Calculation Sheet.

5.7 Method Validation

  1. Validate IVPT method as per EMA and FDA guidelines:
    • Precision: RSD ≤ 10% between replicate cells.
    • Recovery: 90%–110% recovery from receptor fluid.
    • Linearity: R² ≥ 0.99 for standard curve.
    • Sensitivity: LLOQ should detect lowest permeated concentration.
    • Robustness: Reproducibility with different analysts or membranes.
  2. Compile data in Annexure-3: IVPT Validation Summary.

6. Abbreviations

  • IVPT: In-Vitro Permeation Testing
  • PVDF: Polyvinylidene Fluoride
  • PBS: Phosphate Buffered Saline
  • Kp: Permeability Coefficient
  • SOP: Standard Operating Procedure
See also  Analytical Method Development: Method Optimization Protocol - V 2.0

7. Documents

  1. IVPT Sample Log – Annexure-1
  2. IVPT Calculation Sheet – Annexure-2
  3. IVPT Validation Summary – Annexure-3

8. References

  • FDA Guidance on Topical and Transdermal Drug Products — IVPT Studies
  • EMA Guideline on Quality of Topical Products
  • ICH Q2(R2) – Validation of Analytical Procedures
  • USP <1724> – Semisolid Drug Product Performance Tests

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: IVPT Sample Log

Sample ID Time Point (h) Volume Withdrawn (µL) Concentration (µg/mL) Analyst
TP-102 2 200 14.6 Rajesh Kumar

Annexure-2: IVPT Calculation Sheet

Time (h) Cumulative Amount (µg/cm²) Flux (µg/cm²/h) Kp (cm/h)
2 25.6 12.8 0.0041

Annexure-3: IVPT Validation Summary

Parameter Result Criteria Status
Precision RSD = 7.2% ≤ 10% Pass
Recovery 103% 90%–110% Pass

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Revised sampling intervals and included application of steady-state calculations Annual SOP Review
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Biosimilars: SOP for Buffer Preparation for Harvest Operations – V 2.0
Next Post: Sterile Injectable Manufacturing: SOP for Sealing and Labeling of Injectable Vials – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version